http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전기근육자극 훈련이 복부비만 중년 여성의 복부지방, 체간 근 두께와 활성도에 미치는 영향
유승아 ( Seung-ah Yoo ),유기웅 ( Kee-ung Yoo ),임창하 ( Chang-ha Lim ),김창용 ( Chang-yong Kim ),김형동 ( Hyeong-dong Kim ) 대한물리의학회 2019 대한물리의학회지 Vol.14 No.2
PURPOSE: This study examined the effects of low frequency neuromuscular electrical stimulation (NMES) training on abdominal obesity in middle-aged women through electromyography and ultrasound. METHODS: Twenty-two middle aged women with abdominal obesity participated in the study. A low-frequency NMES device was used on the abdomen and waist of each subject for 20 minutes each (a total of 40 minutes) three times a week for eight weeks. The waist-hip ratio (WHR), weight and BMI (Body Mass Index) were measured. Electromyography (EMG) and ultrasound measurements were performed three times in total (pre-intervention, four weeks into the intervention, and eight weeks post-intervention) to examine the effects of low-frequency NMES on the abdominal muscle activity, muscle thickness, and subcutaneous fat. RESULTS: The results indicated a difference in the WHR and waist circumference before and after intervention (p< .05). The external oblique muscle (EO) showed a significant increase in muscle activity during all measurements taken post-intervention (p<.05). The abdominal subcutaneous fat thickness also showed a significant decrease between each measurement (p<.05). The test results showed that the abdominal subcutaneous fat thickness values taken eight weeks post-intervention were significantly lower than those taken pre-intervention and four weeks into the intervention (p<.05). CONCLUSION: These findings show that low-frequency NMES device training can be applied to middle-aged women with abdominal obesity to improve their body shape and exercise performance.
피부섬유아세포에서 저산소증에 의한 Connective Tissue Growth Factor의 발현
홍경희 ( Kyung Hee Hong ),유승아 ( Seung Ah Yoo ),강순숙 ( Soon Sook Kang ),신용주 ( Yong Ju Shin ),김완욱 ( Wan Uk Kim ),조철수 ( Chul Soo Cho ) 대한류마티스학회 2004 대한류마티스학회지 Vol.11 No.4
Objective: Connective tissue growth factor (CTGF) has been proposed to play a role in fibrotic process of systemic sclerosis. Since hypoxia was known to be associated with fibrosis in several profibrogenic conditions, we investigated whether CTGF expression in dermal fibroblast is regulated by hypoxia caused by microvascular loss. Methods: Dermal fribroblasts from patient with systemic sclerosis and normal controls were cultured in the presence of cobalt chloride (CoCl2), a chemical inducer of HIF-1α or hypoxic culture conditions. Expression of HIF-1α, VEGF and CTGF was evaluated by semiquantitative reverse transcription-polymerase chain reaction and Western blotting. Results: Scleroderma fibroblasts expressed increased levels of HIF-1α, VEGF and CTGF compared to normal dermal fibroblasts. Dermal fibroblasts exposed to various concentration of CoCl2 (1∼100μM) enhanced the expression of CTGF mRNA in dose-dependent fashion. Actinomycin D significantly blocked the hypoxia-mediated up-regulation of CTGF mRNA expression, whereas cycloheximide did not block the up-regulation. Up-regulation of CTGF by hypoxia was not mediated by endogenous production of transforming growth factor (TGF)-β. In time-kinetics study, dermal fibroblasts from scleroderma patients exhibited earlier peak expression of CTGF mRNA than those from normal dermal fibroblasts. In addition, simultaneous treatment of suboptimal concentration of CoCl2 and TGF-β exhibited the up-regulation of CTGF mRNA in additive fashion. Interferon-γ did not modulate the expression of CTGF mRNA induced by CoCl2, while the up-regulation of CTGF by TGF-β was downregulated by Interferon-γ in a dose-dependent fashion. Conclusion: These data indicate that hypoxia up-regulates the expression of CTGF in dermal fibroblasts and provide the evidence that hypoxia caused by microvascular alterations contributes the progression of fibrosis in systemic sclerosis by up-regulation of CTGF.
박효은 ( Hyo Eun Park ),유승아 ( Seung Ah Yoo ),박현정 ( Hyun Jeong Park ),김미리 ( Miri Kim ) 대한피부과학회 2020 대한피부과학회지 Vol.58 No.5
Background: Trachyonychia is a condition characterized by longitudinal ridging, pitting, and roughness of the nail surface. It tends to be resistant to various treatment modalities, often leading to a clinically unsatisfactory outcome. Alitretinoin (9-cis-retinoic acid; Alitoc Capsule) is approved for patients with severe chronic hand eczema and has been shown to be effective for other skin diseases. However, only few studies have demonstrated the efficacy of oral alitretinoin for the treatment of trachyonychia. Objective: We aimed to evaluate the efficacy and safety of oral alitretinoin therapy for the treatment of trachyonychia. Methods: We reviewed the medical records and clinical photographs of patients with trachyonychia who were treated with oral alitretinoin therapy between January 2016 and December 2019 in the Department of Dermatology of Yeouido St. Mary’s Hospital. Photographs of the lesions were taken and evaluated at 0, 1, 3, 6, and 12 months. The severity of trachyonychia was assessed into 5 grades according to the roughness of the nail and the distribution of affected areas. Results: Thirty patients (male: 12, female: 18) with a mean age of 51.5±11.1 years were included in the study. After treatment with oral alitretinoin at a dosage of 10∼30 mg/day, the severity of trachyonychia tended to decrease as the number of treatment sessions increased. The mean treatment duration was 6.9±4.1 months. The therapeutic effects were as follows. After 3 months of treatment, 88.0% of the patients showed partial remission, and all the patients showed improvement after >6 months of treatment. After 12 months of treatment, 20.0% of the patients achieved complete remission. Conclusion: Oral alitretinoin therapy may be an effective and safe treatment option for trachyonychia. (Korean J Dermatol 2020;58(5):299∼304)
혈관내피 성장인자를 차단하는 합성 펩타이드인 RRKRRR이 류마티스 염증반응에 미치는 영향
김완욱 ( Wan Uk Kim ),유승아 ( Seung Ah Yoo ),김해림 ( Hae Rim Kim ),박보형 ( Bo Hyoung Park ),민정요 ( Jeong Yo Min ),윤종현 ( Chong Hyeon Yoon ),박성환 ( Sung Hwan Park ),조철수 ( Chul Soo Cho ) 대한류마티스학회 2005 대한류마티스학회지 Vol.12 No.1
Objective: Vascular endothelial growth factor (VEGF) has been suggested to play a critical role in the pathogenesis of rheumatoid arthritis (RA). It has been demonstrated that synthetic arginine-rich hexapeptide, RRKRRR, shows significant inhibition of VEGF-induced angiogenesis, and also retarded the growth and metastasis of colon carcinoma cell by blocking the interaction between VEGF and its receptor. In this study, we investigated whether anti-VEGF RRKRRR peptide (dRK6) could regulate the activation of mononuclear cells of RA patients and suppress collagen-induced arthritis (CIA) in mice. Methods: Synovial fluid mononuclear cells (SFMC) or synoviocytes from RA patients were cultured in the presence of VEGF, and the levels of TNF-α and IL-6 were determined in the culture supernatants by ELISA. Blocking experiments were performed by adding dRK6 to thecells stimulated with VEGF. Additionally, the in vivo effect of dRK6 on the development of arthritis was tested in collagen induced arthritis (CIA) in DBA/1 mice. T cell responses to type II collagen (CII) and IgG antibodies to CII were examined in draining lymph node cells and sera of the mice, respectively. Results: dRK6 showed concentration-dependent inhibitory activity for the VEGF binding to its receptor on human vascular endothelial cells. The treatment of dRK6 completely abrogated the VEGF-induced productions of TNF-α and IL-6 by RA SFMC or synoviocytes. Moreover, a subcutaneous injection of dRK6 resulted in a dose-dependent decrease in the severity and incidence of CIA in mice. In these mice, the T cell responses to type II collagen (CII) in lymph node cells and circulating IgG antibodies to CII were also dose-dependently inhibited by the peptides. Conclusion: We observed firstly that anti-VEGF dRK6 blocked the VEGF-induced production of pro-inflammatory cytokine from RA SFMC and synoviocytes, and suppressed the ongoing paw inflammation in mice. These data suggest that dRK6 may be an effective strategy in the treatment of RA, and could be applied to modulate various chronic VEGF-dependent inflammatory diseases.
고혁재 ( Hyeok Jae Ko ),유승아 ( Seung Ah Yoo ),우성용 ( Seong Yong Woo ),김해림 ( Hae Rim Kim ),조철수 ( Chul Soo Cho ),김완욱 ( Wan Uk Kim ) 대한류마티스학회 2004 대한류마티스학회지 Vol.11 No.2
Objective: Vascular endothelial growth factor (VEGF), an angiogenic factor, has been suggested to play a critical role in the pathogenesis of rheumatoid arthritis (RA). In this study, we investigated whether VEGF would directly regulate the activation of mononuclear cells of RA patients. Methods: Mononuclear cells and/or synoviocytes of RA patients were cultured in the presence of VEGF, and the levels of TNF-α and IL-6 were determined in the culture supernatants by ELISA. The TNF-α-or IL-6-producing cells were also assessed by flow cytometry analysis. Blocking experiments were performed by adding anti-VEGF receptor (anti-Flt-1) mAb to the cells, stimulated with VEGF. Results: VEGF directly increased the productions of TNF-α and IL-6 from peripheral blood mononuclear cells (PBMC) from healthy controls. Treatment of PBMC with anti-VEGF receptor (anti-Flt-1) mAb blocked the VEGF-induced productions of TNF-α and IL-6, suggesting that VEGF activates the PBMC via a receptor (Flt-1) coupling event. Synovial fluid mononuclear cells (SFMC) of RA patients showed a greater response to VEGF stimulation than the PBMC of healthy controls. The major cell types responding to VEGF were monocytes and synoviocytes. In addition, dexamethasone completely abrogated VEGF- stimulated productions of TNF-α and IL-6 from adherent cells, isolated from SFMC. Conclusion: Our data suggest that VEGF may directly activate RA monocytes and synoviocytes to produce TNF-α and IL-6.
무릎 골관절염 환자에서 초음파로 평가된 위중도와 연골 및 활막의 생화학적 지표 간의 상관관계
정영옥 ( Young Ok Jung ),김해림 ( Hae Rim Kim ),강효종 ( Hyo Jong Kang ),유승아 ( Seung Ah Yoo ),나종명 ( Jong Myoung Nah ),조철수 ( Chul Soo Cho ),김호연 ( Ho Youn Kim ),김완욱 ( Wan Uk Kim ) 대한류마티스학회 2004 대한류마티스학회지 Vol.11 No.1
Objective: Ultrasonography has benefit in detecting soft tissue abnormalities within the joints, which cannot be assessed by conventional X-ray. In this study, we investigated the relationship between soft tissue and/or bony abnormalities on ultrasonography and biochemical markers of synovium and cartilage in knee osteoarthritis (OA) patients Methods: Fifty-one knee OA patients who fulfilled the ACR criteria were enrolled in this study. Knee ultrasonography was performed in affected knee joints with a 12 MHz linear probe to assess the presence of effusion, synovial proliferation, capsular distension, length of osteophytes, and thickness of cartilage. At the same time, the serum levels of hyaluronic acid (HA) and cartilage oligomeric protein (COMP) were measured by ELISA and serum osteocalcin levels were determined by RIA. Results: The patients with longer medial osteophytes showed higher levels of serum HA and COMP than those with shorter ones. Serum HA levels were significantly higher in patients with larger amount of effusion and/or synovial proliferation, suggesting inflammatory changes within the joint, than those without. In addition, the severity of capsular distention was also correlated well with serum HA and COMP levels. However, the length of lateral osteophytes and thickness of femoral cartilage were not correlated with serum HA or COMP levels. Serum osteocalcin levels did not show any association with above ultrasonographic parameters, either. Conclusion: Using knee ultrasonography, we demonstrated that serum HA and COMP levels were elevated in more severe OA patients than less severe patients. This result suggests that detailed pathologic changes in the soft tissue and/or bone of OA joints on ultrasonography are being directly reflected to biochemical markers measured in the peripheral blood.
전신흥반루푸스 환자에서 혈청 Osteoprotegerin 증가
신용주 ( Yong Ju Shin ),홍경희 ( Kyung Hee Hong ),유승아 ( Seung Ah Yoo ),최진정 ( Jin Jung Choi ),김완욱 ( Wan Uk Kim ),조철수 ( Chul Soo Cho ) 대한류마티스학회 2006 대한류마티스학회지 Vol.13 No.3
Objective: To determine the serum levels of soluble osteoprotegerin (OPG), decoy receptor of receptor activator of nuclear factor kB ligand (RANKL), in patients with systemic lupus erythematosus (SLE) and to assess the its relationships with certain clinical manifestations. Methods: Serum levels of OPG in 60 patients with SLE and 30 healthy controls were determined by enzyme-linked immunosorbent assay. At the time of serum sampling, clinical manifestations and lupus disease activity index (SLEDAI) were assessed. Results: Serum levels of OPG in 60 patients with SLE were significantly higher than in 30 healthy controls (1,058±699 versus 806±113 pg/mL, p=0.008). Patients with active disease had higher levels of OPG levels than those with inactive disease (1,355±837 versus 760±113 pg/mL, p<0.001). Serum OPG levels correlated with SLEDAI (γ=0.588, p<0.0001), anti-dsDNA antibody titers (γ=0.337, p=0.009) and serum MCP-1 levels (γ=0.485, P<0.0001). In particular, serum OPG levels were found to be significantly increased in patients with neurological manifestation compared to those without (1,504±1,152 versus 918±376 pg/mL, p=0.004). Conclusion: The results of this study suggest that serum OPG levels are increased in patients with SLE. Serum OPG has a role as marker for disease activity and its increased levels reflect the involvement of neurological manifestation.